Volgen
Erik M Volz
Titel
Geciteerd door
Geciteerd door
Jaar
Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand
NM Ferguson, D Laydon, G Nedjati-Gilani, N Imai, K Ainslie, M Baguelin, ...
Imperial College London, 2020
51532020
Estimates of the severity of coronavirus disease 2019: a model-based analysis
R Verity, LC Okell, I Dorigatti, P Winskill, C Whittaker, N Imai, ...
The Lancet infectious diseases 20 (6), 669-677, 2020
45482020
Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
S Flaxman, S Mishra, A Gandy, HJT Unwin, TA Mellan, H Coupland, ...
Nature 584 (7820), 257-261, 2020
4279*2020
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study
T Nyberg, NM Ferguson, SG Nash, HH Webster, S Flaxman, N Andrews, ...
The lancet 399 (10332), 1303-1312, 2022
12802022
Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England
E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, ...
Nature 593 (7858), 266-269, 2021
12282021
Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity
E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ...
Cell 184 (1), 64-75. e11, 2021
11752021
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study
KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ...
The Lancet Infectious Diseases 22 (1), 35-42, 2022
8972022
Disability and health
World Health Organization
Niepełnosprawność-zagadnienia, problemy, rozwiązania, 74-78, 2020
887*2020
Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
R Andrew
Virological, 2020
8212020
Probability based estimation theory for respondent driven sampling
E Volz, DD Heckathorn
Journal of official statistics 24 (1), 79, 2008
7862008
Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data
E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, ...
MedRxiv, 2020.12. 30.20249034, 2021
6282021
Reduction in mobility and COVID-19 transmission
P Nouvellet, S Bhatia, A Cori, KEC Ainslie, M Baguelin, S Bhatt, ...
Nature communications 12 (1), 1-9, 2021
6242021
Viral phylodynamics
EM Volz, K Koelle, T Bedford
PLoS computational biology 9 (3), e1002947, 2013
5242013
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7
B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ...
Cell reports 35 (13), 2021
4692021
Estimates of the severity of COVID-19 disease
R Verity, LC Okell, I Dorigatti, P Winskill, C Whittaker, N Imai, ...
MedRxiv, 2020.03. 09.20033357, 2020
4302020
SIR dynamics in random networks with heterogeneous connectivity
E Volz
Journal of mathematical biology 56, 293-310, 2008
4202008
Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK
L Du Plessis, JT McCrone, AE Zarebski, V Hill, C Ruis, B Gutierrez, ...
Science 371 (6530), 708-712, 2021
4082021
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study
MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ...
The Lancet Public Health 6 (5), e335-e345, 2021
3752021
Susceptible–infected–recovered epidemics in dynamic contact networks
E Volz, LA Meyers
Proceedings of the Royal Society B: Biological Sciences 274 (1628), 2925-2934, 2007
3492007
Edge-based compartmental modelling for infectious disease spread
JC Miller, AC Slim, EM Volz
Journal of the Royal Society Interface 9 (70), 890-906, 2012
2952012
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20